Cascadian Therapeutics Announces Changes to Board of Directors
March 13 2017 - 4:01PM
Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage
biopharmaceutical company, today announced that Robert W. Azelby
has been appointed to the Company’s Board of Directors. Mr. Azelby
is a biotechnology and pharmaceutical industry veteran. He
currently serves as Executive Vice President and Chief Commercial
Officer of Juno Therapeutics. The Company also announced that
Richard L. Jackson, Ph.D. retired from the Board as of March 8,
2017.
“I would like to thank Dr. Jackson for his years of service as a
director and welcome Mr. Azelby to the team,” said Dr. Christopher
S. Henney, Chairman of Cascadian Therapeutics’ Board of Directors.
“Mr. Azelby’s background in product development, market access and
commercial operations will provide a strong addition to our
Board.”
“I am delighted to join Cascadian Therapeutics’ Board of
Directors and offering my experience at this pivotal time while the
company advances tucatinib into late-stage development,” said Mr.
Azelby.
Robert Azelby has served as Chief Commercial Officer at Juno
Therapeutics since November 2015. Prior to Juno, he was with Amgen
for 15 years, serving most recently as Vice President and General
Manager of Amgen’s $6 billion U.S. Oncology business.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical
company dedicated to developing innovative product candidates for
the treatment of cancer. The lead product candidate, tucatinib, is
an oral, selective small molecule HER2 inhibitor. Cascadian
Therapeutics is conducting a randomized, double-blind controlled
pivotal clinical trial called HER2CLIMB, which is comparing
tucatinib vs. placebo in combination with capecitabine and
trastuzumab in patients with locally advanced or metastatic
HER2-positive breast cancer with and without brain metastases, who
have previously been treated with a taxane, trastuzumab, pertuzumab
and T-DM1. Additional details on HER2CLIMB can be found at
www.clinicaltrials.gov (Identifier: NCT02614794) or
www.HER2CLIMB.com. For more information, please
visit www.cascadianrx.com.
Forward-Looking Statements
In order to provide Cascadian Therapeutics' investors with an
understanding of its current results and future prospects, this
release contains statements that are forward-looking. Any
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"will," "intends," "potential," "possible" and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements include Cascadian Therapeutics'
expectations regarding clinical development activities and
potential benefits of tucatinib. Forward-looking statements involve
risks and uncertainties related to Cascadian Therapeutics' business
and the general economic environment, many of which are beyond its
control. These risks, uncertainties and other factors could cause
Cascadian Therapeutics' actual results to differ materially from
those projected in forward-looking statements, including the risks
associated with the costs and expenses of developing its product
candidates, the adequacy of financing and cash, cash equivalents
and investments, changes in general accounting policies, general
economic factors, achievement of the results it anticipates from
its preclinical development and clinical trials of its product
candidates and its ability to adequately obtain and protect its
intellectual property rights. Although Cascadian Therapeutics
believes that the forward-looking statements contained herein are
reasonable, it can give no assurance that its expectations are
correct. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement. For a detailed
description of Cascadian Therapeutics' risks and uncertainties, you
are encouraged to review the documents filed with the securities
regulators in the United States on EDGAR and in Canada on SEDAR.
Except as required by law, Cascadian Therapeutics does not
undertake any obligation to publicly update its forward-looking
statements based on events or circumstances after the date
hereof.
Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
mgreer@cascadianrx.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Sep 2023 to Sep 2024